Glaukos Corporation (NYSE:GKOS) Given Average Recommendation of "Moderate Buy" by Brokerages

Glaukos Corporation (NYSE:GKOS - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the fourteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $144.4167.

Several research firms have commented on GKOS. Stifel Nicolaus set a $170.00 target price on shares of Glaukos in a research report on Thursday, April 30th. Weiss Ratings reissued a "sell (d-)" rating on shares of Glaukos in a research report on Tuesday, April 21st. Piper Sandler reissued an "overweight" rating and issued a $165.00 target price on shares of Glaukos in a research report on Wednesday, January 14th. Wells Fargo & Company boosted their target price on shares of Glaukos from $135.00 to $138.00 and gave the stock an "overweight" rating in a research report on Thursday, April 30th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Glaukos from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Thursday, April 30th.

Glaukos Stock Down 0.7%

Glaukos stock opened at $133.16 on Friday. The firm has a market cap of $7.82 billion, a PE ratio of -40.60 and a beta of 0.94. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.73 and a current ratio of 5.43. The firm's 50 day moving average price is $114.89 and its two-hundred day moving average price is $109.04. Glaukos has a twelve month low of $73.16 and a twelve month high of $146.75.

Glaukos (NYSE:GKOS - Get Free Report) last posted its earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.12. The company had revenue of $150.57 million during the quarter, compared to the consensus estimate of $137.00 million. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The company's revenue for the quarter was up 41.2% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.22) earnings per share. On average, research analysts predict that Glaukos will post -0.57 EPS for the current fiscal year.

Insider Buying and Selling at Glaukos

In other Glaukos news, Director Leana Wen sold 1,700 shares of the business's stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $143.35, for a total value of $243,695.00. Following the completion of the sale, the director directly owned 19,739 shares of the company's stock, valued at $2,829,585.65. The trade was a 7.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Joseph E. Gilliam sold 19,573 shares of the business's stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $143.54, for a total transaction of $2,809,508.42. Following the completion of the sale, the chief operating officer directly owned 73,419 shares of the company's stock, valued at $10,538,563.26. This represents a 21.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 50,930 shares of company stock valued at $6,703,263. 5.80% of the stock is currently owned by insiders.

Institutional Trading of Glaukos

Several large investors have recently modified their holdings of the company. Smartleaf Asset Management LLC boosted its holdings in shares of Glaukos by 9.7% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,383 shares of the medical instruments supplier's stock worth $158,000 after buying an additional 122 shares during the period. Larson Financial Group LLC boosted its holdings in shares of Glaukos by 62.0% during the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier's stock worth $39,000 after buying an additional 132 shares during the period. CWM LLC boosted its holdings in shares of Glaukos by 25.2% during the 4th quarter. CWM LLC now owns 710 shares of the medical instruments supplier's stock worth $80,000 after buying an additional 143 shares during the period. Commonwealth Equity Services LLC boosted its holdings in shares of Glaukos by 1.7% during the 4th quarter. Commonwealth Equity Services LLC now owns 8,383 shares of the medical instruments supplier's stock worth $947,000 after buying an additional 144 shares during the period. Finally, Evergreen Capital Management LLC boosted its holdings in shares of Glaukos by 4.3% during the 4th quarter. Evergreen Capital Management LLC now owns 3,549 shares of the medical instruments supplier's stock worth $401,000 after buying an additional 145 shares during the period. 99.04% of the stock is owned by institutional investors.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.